Biomarkers
TMB-High
Also known as: High tumor mutational burden
Definition
Tumor mutational burden of ≥10 mutations/megabase, associated with better response to checkpoint inhibitors and an FDA tissue-agnostic indication.
Detailed Explanation
High TMB increases neoantigen load, improving immunogenicity. Keytruda has a tissue-agnostic approval for TMB-high tumors.